X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (50874) 50874
Publication (4136) 4136
Newspaper Article (750) 750
Book Review (554) 554
Book Chapter (223) 223
Newsletter (216) 216
Conference Proceeding (45) 45
Magazine Article (34) 34
Dissertation (33) 33
Trade Publication Article (20) 20
Book / eBook (13) 13
Data Set (11) 11
Reference (7) 7
Transcript (7) 7
Presentation (5) 5
Government Document (4) 4
Paper (2) 2
Journal / eJournal (1) 1
Report (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (41172) 41172
chemotherapy (32293) 32293
female (30486) 30486
index medicus (29893) 29893
oncology (27587) 27587
middle aged (23738) 23738
cancer (22662) 22662
aged (21210) 21210
male (20649) 20649
adult (18195) 18195
surgery (15526) 15526
prognosis (13947) 13947
treatment outcome (12719) 12719
chemotherapy, adjuvant (12664) 12664
survival (11819) 11819
neoplasm staging (11158) 11158
antineoplastic combined chemotherapy protocols - therapeutic use (10782) 10782
care and treatment (10358) 10358
retrospective studies (10119) 10119
survival rate (9303) 9303
breast cancer (8960) 8960
aged, 80 and over (8716) 8716
metastasis (8462) 8462
combined modality therapy (7897) 7897
medicine & public health (7878) 7878
radiotherapy (7838) 7838
disease-free survival (7767) 7767
cancer therapies (7600) 7600
survival analysis (7351) 7351
tumors (7241) 7241
analysis (7188) 7188
research (7032) 7032
health aspects (6460) 6460
follow-up studies (6358) 6358
patients (6347) 6347
carcinoma (6169) 6169
adjuvant chemotherapy (6163) 6163
therapy (5766) 5766
risk factors (5435) 5435
mortality (5426) 5426
medical prognosis (5353) 5353
breast neoplasms - drug therapy (5086) 5086
colorectal cancer (4633) 4633
antineoplastic agents - therapeutic use (4561) 4561
breast neoplasms - mortality (4442) 4442
radiation therapy (4320) 4320
kaplan-meier estimate (4221) 4221
breast neoplasms - pathology (4201) 4201
radiotherapy, adjuvant (4104) 4104
patient outcomes (3847) 3847
neoadjuvant therapy (3793) 3793
hematology, oncology and palliative medicine (3695) 3695
time factors (3659) 3659
adjuvant treatment (3622) 3622
adolescent (3452) 3452
multivariate analysis (3440) 3440
studies (3420) 3420
young adult (3320) 3320
clinical trials (3311) 3311
cisplatin (3291) 3291
proportional hazards models (3202) 3202
trial (3151) 3151
radiation-therapy (3150) 3150
lymphatic metastasis (3148) 3148
antineoplastic combined chemotherapy protocols - adverse effects (3142) 3142
diagnosis (3139) 3139
cancer patients (3080) 3080
adenocarcinoma (3074) 3074
neoadjuvant chemotherapy (3060) 3060
drug therapy (3035) 3035
recurrence (2975) 2975
prospective studies (2957) 2957
oncology, experimental (2889) 2889
fluorouracil - administration & dosage (2856) 2856
medical research (2795) 2795
metastases (2770) 2770
management (2701) 2701
randomized-trial (2584) 2584
development and progression (2529) 2529
radiation (2495) 2495
abridged index medicus (2494) 2494
expression (2465) 2465
fluorouracil (2447) 2447
cisplatin - administration & dosage (2444) 2444
adenocarcinoma - mortality (2434) 2434
gastroenterology & hepatology (2421) 2421
women (2406) 2406
medicine (2375) 2375
lung cancer (2362) 2362
usage (2337) 2337
colorectal neoplasms - pathology (2335) 2335
surgical oncology (2302) 2302
chemoradiotherapy (2270) 2270
neoplasm metastasis (2252) 2252
risk (2234) 2234
risk assessment (2203) 2203
antineoplastic combined chemotherapy protocols - administration & dosage (2196) 2196
gene expression (2194) 2194
cancer research (2154) 2154
resection (2139) 2139
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (50267) 50267
German (754) 754
Japanese (496) 496
French (377) 377
Chinese (134) 134
Russian (104) 104
Spanish (92) 92
Italian (76) 76
Polish (38) 38
Hungarian (31) 31
Danish (26) 26
Dutch (21) 21
Korean (19) 19
Romanian (13) 13
Czech (12) 12
Portuguese (12) 12
Turkish (11) 11
Lithuanian (10) 10
Swedish (9) 9
Ukrainian (8) 8
Finnish (6) 6
Norwegian (6) 6
Bulgarian (5) 5
Hebrew (5) 5
Icelandic (5) 5
Arabic (4) 4
Serbian (2) 2
Latvian (1) 1
Slovak (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet Oncology, ISSN 1470-2045, 01/2018, Volume 19, Issue 1, pp. 139 - 148
Cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT... 
CELL LUNG-CANCER | SURVIVAL | FORTHCOMING 7TH EDITION | 1ST-LINE TREATMENT | PLACEBO | ESMO CONSENSUS CONFERENCE | THERAPY | ONCOLOGY | TNM CLASSIFICATION | ERLOTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Pneumonectomy | Protein Kinase Inhibitors - adverse effects | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Young Adult | Time Factors | Vinblastine - analogs & derivatives | Vinblastine - adverse effects | China | Adult | Female | Quinazolines - administration & dosage | Chemotherapy, Adjuvant | Gefitinib | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Risk Factors | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Quinazolines - adverse effects | Cisplatin - adverse effects | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Vinorelbine | Lung cancer, Non-small cell | Care and treatment
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10073, pp. 1011 - 1024
Summary Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THERAPY | ADENOCARCINOMA | CHEMORADIOTHERAPY | FOLINIC ACID | MODEL | CHEMOTHERAPY | Capecitabine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Carcinoma, Pancreatic Ductal - surgery | Antimetabolites, Antineoplastic - administration & dosage | Pancreatic Neoplasms - drug therapy | Aged, 80 and over | Adult | Carcinoma, Pancreatic Ductal - mortality | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Chemotherapy, Adjuvant | Deoxycytidine - administration & dosage | Pancreatic Neoplasms - surgery | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Pancreatic Ductal - drug therapy | Capecitabine - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Aged | Deoxycytidine - analogs & derivatives | Antimitotic agents | Cancer patients | Care and treatment | Pancreatic cancer | Clinical trials | Product development | Metastasis | Comparative analysis | Antineoplastic agents | Studies | Antigens | Chemotherapy | Acids | Pragmatism | Pharmaceutical industry | Cancer therapies | Abdomen | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1344 - 1354
Summary Background There is no standard of care for adjuvant therapy for patients with hepatocellular carcinoma. This trial was designed to assess the efficacy... 
Hematology, Oncology and Palliative Medicine | CLINICAL-PRACTICE GUIDELINES | DIAGNOSIS | LIVER-TRANSPLANTATION | RISK-FACTORS | THERAPY | MANAGEMENT | ONCOLOGY | SAFETY | PREVENTION | RECURRENCE | Catheter Ablation - mortality | South America | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Hepatectomy - mortality | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | North America | Young Adult | Carcinoma, Hepatocellular - drug therapy | Time Factors | Aged, 80 and over | Liver Neoplasms - pathology | Catheter Ablation - adverse effects | Chemotherapy, Adjuvant | Europe | Risk Factors | Niacinamide - adverse effects | Niacinamide - therapeutic use | Disease Progression | New Zealand | Protein Kinase Inhibitors - administration & dosage | Intention to Treat Analysis | Niacinamide - analogs & derivatives | Liver Neoplasms - mortality | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adult | Female | Double-Blind Method | Hepatectomy - adverse effects | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Neoplasm Recurrence, Local | Phenylurea Compounds - therapeutic use | Carcinoma, Hepatocellular - surgery | Liver Neoplasms - surgery | Treatment Outcome | Niacinamide - administration & dosage | Disease-Free Survival | Phenylurea Compounds - administration & dosage | Asia | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Aged | Australia | Antimitotic agents | Liver cancer | Medical colleges | Surgery | Liver | Clinical trials | Hepatoma | Antineoplastic agents
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 19, pp. 1845 - 1855
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 19, pp. 1813 - 1823
In patients with surgically resected melanoma, those with BRAF mutations who received 1 year of oral adjuvant therapy with dabrafenib and trametinib had a 53%... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | INTERFERON-ALPHA-2B | PLACEBO | THERAPY | MEK INHIBITION | PHASE-III | DOUBLE-BLIND | HAZARD | IPILIMUMAB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Adjuvants, Immunologic - adverse effects | Young Adult | Melanoma - genetics | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Double-Blind Method | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasm Recurrence, Local | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Adolescent | Survival Analysis | Aged | Pyridones - therapeutic use | Melanoma - surgery | Mutation | Neoplasm Staging | Pyridones - adverse effects | Melanoma - mortality | Usage | Relapse | Patient outcomes | Analysis | Melanoma | Adjuvant treatment | Outcome and process assessment (Health Care) | Reports | Drug therapy | Cancer | Diseases | Medical imaging | Oncology | Metastasis | FDA approval | Kinases | Cancer therapies | Survival | Skin cancer | Metastases | Medical prognosis | Immunotherapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9813, pp. 315 - 321
Journal Article